Jack Bendheim sold $757k of PAHC
President and CEO at PHIBRO ANIMAL HEALTH CORP. 14,080 shares at an average of $53.75, traded Mar 30, 2026, filed Mar 31, 2026.
Score components
- +25RoleCEO
- +22Trade size$757k at market
- +10Share of holdings soldSold 27% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.9%, 3m -43.0%, 6m -35.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-037978, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | SOpen-market sale Class A Common Stockindirect: See10b5-1 | -6,423 | $53.54 | $344k | 45,777 | Mar 31, 2026 |
| Mar 30, 2026 | SOpen-market sale Class A Common Stockindirect: See10b5-1 | -617 | $54.31 | $34k | 45,160 | Mar 31, 2026 |
| Mar 31, 2026 | SOpen-market sale Class A Common Stockindirect: See10b5-1 | -6,609 | $53.87 | $356k | 38,551 | Mar 31, 2026 |
| Mar 31, 2026 | SOpen-market sale Class A Common Stockindirect: See10b5-1 | -431 | $54.35 | $23k | 38,120 | Mar 31, 2026 |
Related signals
Other insiders at PHIBRO ANIMAL HEALTH CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | PAHCbuy PHIBRO ANIMAL HEALTH CORP | E Thomas Corcoran director | $318k 10,000 shares | +32% | |
| 35Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.0M 18,608 shares | -25% | |
| 35Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.1M 21,120 shares | -22% | |
| 35Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.2M 21,120 shares | -18% | |
| 50Moderate | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.2M 21,120 shares | -55% | |
| 40Moderate | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.2M 21,120 shares | -29% | |
| 35Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.2M 22,880 shares | -24% | |
| 18Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $258k 5,280 shares | -5% | |
| 50Moderate | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $1.1M 21,120 shares | -93% | |
| 36Weak | PHIBRO ANIMAL HEALTH CORP | Jack Bendheim President and CEO | $716k 14,080 shares | -38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.